Natera, Inc. (“Natera”) is a diagnostics company with proprietary molecular and bioinformatics technology. Natera has developed and commercialized non- or minimally invasive tests for women’s health to evaluate risk for, and enable early detection of, a wide range of genetic conditions. Natera’s technology is also being used in the oncology market, including the commercialization of a personalized blood-based DNA test to detect molecular residual disease and monitor disease recurrence, as well as in the organ health market, with tests to assess organ transplant rejection.